Cargando…
Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide
Background: forgiveness is the ability of a given regimen to maintain complete viral suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir/emtricitabine/tenofovir alafenamide. Methods: drug refills were used to calculate the percent day covered (PDC) as a proxy...
Autores principales: | Maggiolo, Franco, Valenti, Daniela, Teocchi, Rodolfo, Comi, Laura, Di Filippo, Elisa, Rizzi, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703486/ https://www.ncbi.nlm.nih.gov/pubmed/36423244 http://dx.doi.org/10.1177/23259582221140208 |
Ejemplares similares
-
Adherence to and Forgiveness
of 3TC/DTG in a Real-World Cohort
por: Maggiolo, Franco, et al.
Publicado: (2022) -
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018) -
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023) -
Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey
por: Balcı, Umay, et al.
Publicado: (2023) -
Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection
por: Deeks, Emma D.
Publicado: (2018)